Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome

Glioblastoma (GBM) is one of the deadliest human cancers. Because of the extremely unfavorable prognosis of GBM, it is important to develop more effective diagnostic and therapeutic strategies based on biologically and clinically relevant subclassification systems. Analyzing a collection of seventee...

Descripción completa

Detalles Bibliográficos
Autores principales: Marziali, G., Signore, M., Buccarelli, M., Grande, S., Palma, A., Biffoni, M., Rosi, A., D’Alessandris, Q.G., Martini, M., Larocca, L. M., De Maria, R., Pallini, R., Ricci-Vitiani, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746700/
https://www.ncbi.nlm.nih.gov/pubmed/26857460
http://dx.doi.org/10.1038/srep21557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746700/
https://www.ncbi.nlm.nih.gov/pubmed/26857460
http://dx.doi.org/10.1038/srep21557

Ejemplares similares